Study guide

NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

EBP-EAP Examination in Paediatrics Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Governance, Ethics & Child Safeguarding

EBP-EAP Format, Delivery, Scoring, and Clinical Vignette Strategy Paediatric Ethics, Consent/Assent, Gillick Competence, and Patient Safety Child Protection, Physical/Emotional Abuse, Neglect, and Non-Accidental Injury (NAI)

2 Chapter 2: Neonatal Transition, Resuscitation & Prematurity

Delivery Room Care, Apgar Scoring, and Neonatal Resuscitation Algorithm Respiratory Distress Syndrome (RDS), Surfactant Therapy, and Bronchopulmonary Dysplasia Perinatal Asphyxia, HIE Sarnat Staging, and Therapeutic Hypothermia Protocol

3 Chapter 3: Neonatal Morbidities, Jaundice & Congenital Infections

Unconjugated vs Conjugated Hyperbilirubinemia, Phototherapy Thresholds, and Exchange Transfusion Early- vs Late-Onset Sepsis, Group B Streptococcus, and Congenital TORCH Infections NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

4 Chapter 4: Acute Paediatric Emergencies & Critical Care

EPLS/PALS Structured Approach, Types of Shock, and Weight-Based Fluid Boluses Clinical Diagnostic Criteria, Intramuscular Adrenaline Dosing, and Refractory Anaphylaxis 5-Minute Time-Critical Anticonvulsant Protocol and Status Epilepticus Care Common Toxidromes (Paracetamol, Iron, Caustics, Button Batteries) and Decontamination

5 Chapter 5: Paediatric Respiratory Medicine

Stridor Differential, Croup (Westley Score & Dexamethasone), and Epiglottitis RSV Pathogenesis, Supportive Management, Oxygen/High-Flow Criteria, and Futility of Bronchodilators/Steroids European/BTS Guidelines on Chronic Stepwise Control and Acute Severe Exacerbation Management Community-Acquired Pneumonia Etiology, Parapneumonic Effusion/Empyema, and Cystic Fibrosis Pulmonary Exacerbations

6 Chapter 6: Paediatric Cardiology

Acyanotic vs Cyanotic Congenital Heart Disease: Ductal Patency, Shunt Lesions, and Emergency Stabilization Paediatric Murmurs and Arrhythmias: Innocent vs Pathological Murmurs, SVT, and Resuscitation Protocols Acquired Heart Disease: Kawasaki Disease, Coronary Aneurysm Prevention, and Acute Rheumatic Fever

7 Chapter 7: Paediatric Gastroenterology, Hepatology & Nutrition

Dehydration Severity Assessment, Oral Rehydration Therapy (ORT), and Intravenous Fluid Protocols ESPGHAN Coeliac Diagnostic Criteria (Biopsy-Sparing Pathway) and Paediatric Crohn's/Ulcerative Colitis Breastfeeding, Formula Selection, Cow's Milk Protein Allergy (CMPA), GERD vs GOR, and Faltering Growth Prolonged Neonatal Jaundice Workup, Biliary Atresia Red Flags, and Acute Hepatitis/Liver Failure

8 Chapter 8: Paediatric Nephrology, Fluids & Electrolyte Balance

Paediatric UTI Diagnosis, Imaging Criteria (Ultrasound/DMSA/MCUG), and Vesicoureteral Reflux Minimal Change Nephrotic Syndrome (Steroid Regimen & Complications) vs Acute Post-Infectious Glomerulonephritis Paediatric AKI (pRIFLE/KDIGO), Haemolytic Uraemic Syndrome (HUS), and Hyperkalaemia/Dysnatraemia Management

9 Chapter 9: Paediatric Endocrinology & Inborn Errors of Metabolism

Paediatric DKA Protocol (ISPAD/European Fluid & Insulin Guidelines, Cerebral Oedema Prevention) and T1DM Maintenance Congenital Hypothyroidism Screening & Levothyroxine, Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency), and Adrenal Crisis Short Stature Workup, Precocious vs Delayed Puberty, and Approach to Suspected Inborn Errors of Metabolism (IEM)

10 Chapter 10: Paediatric Neurology, Neurodevelopment & Mental Health

Simple vs Complex Febrile Seizures, Childhood Epilepsy Syndromes (Absence, Infantile Spasms, Benign Rolandic), and Antiseizure Medications Red Flags for Raised Intracranial Pressure (ICP), Brain Tumours, Migraine vs Tension Headache Acute Bacterial Meningitis (LP Contraindications, Ceftriaxone, Dexamethasone) and Viral Encephalitis (Aciclovir) Developmental Milestones (Gross Motor, Fine Motor/Vision, Speech/Language, Social), Autism Spectrum, ADHD, and Cerebral Palsy

11 Chapter 11: Paediatric Haematology & Oncology

Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD) Sickle Cell Crises (Vaso-occlusive, Acute Chest Syndrome, Stroke Prevention), Immune Thrombocytopenia (ITP), and Haemophilia A/B Acute Lymphoblastic Leukaemia (ALL), Neuroblastoma, Wilms Tumour, and Management of Febrile Neutropenia

12 Chapter 12: Paediatric Infectious Diseases, Immunology & Allergy

Common Childhood Exanthems: Clinical Morphology, Timelines, Complications, and Management Paediatric Tuberculosis, Sepsis Six in Children, and Acute Osteoarticular Infections Pediatric Allergy, Atopic Eczema, Food Hypersensitivity, and Desensitization Primary Immunodeficiencies, Warning Signs, Live Vaccine Contraindications, and European Immunisation Schedules

13 Chapter 13: Paediatric Musculoskeletal, Dermatology & Surgical Conditions

The Limping Child, Septic Arthritis vs Transient Synovitis, and Juvenile Idiopathic Arthritis Henoch-Schönlein Purpura, Kawasaki Disease vs MIS-C, Infantile Haemangiomas, and Common Pediatric Eruptions Acute Appendicitis, Intussusception, Pyloric Stenosis, Testicular Torsion, and Incarcerated Hernia

14 Chapter 14: Research Methods, Biostatistics & Evidence-Based Paediatrics

Study Designs, Causality, Bias, and Epidemiological Measures in Paediatrics Diagnostic Test Accuracy, Statistical Inference, and Hypothesis Testing Systematic Reviews, Meta-Analysis, Decision Analysis, and Paediatric Research Ethics

15 Chapter 15: Paediatric Ophthalmology & ENT Disorders

Paediatric Vision Assessment, Refractive Disorders, Strabismus, and Leukocoria Ocular Emergencies, Orbital Infections, ROP, and Systemic Manifestations Paediatric Otolaryngology: Otitis Media, Hearing Impairment, and Upper Airway Conditions

16 Chapter 16: Paediatric Sports Medicine & Musculoskeletal Health

Skeletal Maturity, Physeal Injuries, Apophysitis, and Overuse Syndromes Paediatric Sports Concussion, Second Impact Syndrome, and Return-to-Play Protocols Pre-Participation Screening, Physical Activity Guidelines, and Chronic Disease Clearance

17 Chapter 17: Adolescent Medicine & Healthcare Transition

Biopsychosocial Development, Pubertal Staging, and Adolescent Communication Adolescent Confidentiality, Risk Behaviours, Reproductive Health, and Eating Disorders Chronic Illness in Adolescence and Structured Healthcare Transition

18 Chapter 18: Paediatric Genetics, Dysmorphology & Clinical Genomics

Patterns of Inheritance, Non-Mendelian Mechanisms, and Pedigree Construction Clinical Dysmorphology, Chromosomal Aneuploidies, and Microdeletion Syndromes Genetic Testing Technologies, Prenatal Diagnosis, and Genetic Counselling Ethics

19 Chapter 19: Paediatric Mental Health, Behaviour & Community Medicine

Cognitive Development, Attachment, Screening, and Common Emotional Disorders Regulatory Disorders, Neurodevelopmental Behavioural Conditions, and Psychosomatic Illness Community Child Healthcare Structures, Disability Coordination, and Child Advocacy

NEC Diagnosis/Bell Staging, Neonatal Hypoglycaemia, and Newborn Bloodspot Screening

Key Takeaways Explain This Topic AI

Necrotizing enterocolitis (NEC) results from the interaction of prematurity, formula feeding, pathogenic intestinal dysbiosis, and microvascular ischemia; exclusive human milk feeding is the single most effective preventive measure.

Bell Stage II denotes definite NEC characterized pathognomonically by pneumatosis intestinalis and portal venous gas, while Stage III indicates advanced disease, with Stage IIIB defined by pneumoperitoneum requiring urgent surgical exploration.

Glucose thresholds depend on age and protocol. In the CPS first-72-hour pathway, at-risk glucose <2.6 mmol/L prompts intervention; symptoms or very low glucose (<1.8 mmol/L) require urgent IV glucose, commonly D10W 2 mL/kg followed by infusion. Persistent hypoglycaemia requires higher age- and cause-specific targets.

Recurrent hypoglycaemia or a high glucose requirement (for example, GIR >8 mg/kg/min) should prompt investigation for hyperinsulinism and other causes. During hypoglycaemia, obtain glucose, insulin/C-peptide, ketones, free fatty acids and counter-regulatory hormones without delaying treatment. Diagnosis rests on inappropriate insulin action, not GIR or insulin concentration alone.

Newborn bloodspot sampling times and panels follow national programmes. Common screened disorders include PKU, congenital hypothyroidism, cystic fibrosis, MCADD and sickle cell disease. Take samples at the scheduled age even when milk feeds are not established, and follow laboratory advice about repeat samples.

Last updated: November 2026

Necrotizing Enterocolitis, Neonatal Hypoglycemia, and Metabolic Screening

The neonatal intensive care environment demands rapid clinical recognition of gastrointestinal surgical catastrophes, precise glycemic stabilization to prevent hypoglycemic brain injury, and systematic screening for inborn metabolic and endocrine disorders before irreversible organ damage occurs.

Necrotizing Enterocolitis (NEC): Pathogenesis and Risk Factors

Necrotizing enterocolitis (NEC) is the most common gastrointestinal medical-surgical emergency in the neonatal period, affecting 5% to 10% of very low birth weight (VLBW, <1500 g) infants and up to 10% of infants born at <28 weeks gestation . Premature Intestinal Mucosa

  • Immature tight junctions & high mucosal permeability
  • Deficient goblet cells and mucin barrier
  • Exaggerated Toll-like Receptor 4 (TLR4) inflammatory signaling
  • │
  • ▼
  • Formula Feeding ──────────► Microbial Dysbiosis
  • Hyperosmolar stress - Expansion of Proteobacteria
  • Lack of maternal IgA, - Depletion of commensal Bifidobacteria
  • lactoferrin, & HMOs - Bacterial translocation
  • │
  • ▼
  • Microvascular Ischemia & Reperfusion Injury
  • Platelet-Activating Factor (PAF) release
  • Nitric oxide imbalance & endothelin vasoconstriction
  • │
  • ▼
  • Transmural Intestinal Necrosis & Sepsis
  • Pneumatosis Intestinalis (Gas in bowel wall)
  • Portal Venous Gas
  • Perforation ──► Pneumoperitoneum ──► Peritonitis & Shock
  • Primary Pathophysiological Drivers

Intestinal Immaturity : The preterm gut exhibits deficient enterocyte proliferation, abnormal microvascular autoregulation, and exaggerated expression of Toll-like receptor 4 (TLR4) . In utero, TLR4 promotes normal intestinal development, but after birth, excessive activation of TLR4 by Gram-negative bacterial lipopolysaccharide (LPS) triggers enterocyte apoptosis, microvascular vasoconstriction, and impaired mucosal healing.

Enteral Formula Feeding : Formula feeding provides a substrate for bacterial fermentation, causes hyperosmolar mucosal injury, and lacks the protective bioactive molecules found in human milk (secretory IgA, lactoferrin, human milk oligosaccharides [HMOs], epidermal growth factor, and lysozyme). Exclusive maternal or donor breast milk reduces the incidence of NEC by 50% to 70% .

Intestinal Dysbiosis : Reduced bacterial diversity with an overgrowth of pro-inflammatory Gram-negative Proteobacteria (including Enterobacteriaceae ) and an absence of protective Bifidobacterium species.

Ischemic-Reperfusion Insults : Episodes of systemic hypoperfusion (perinatal asphyxia, severe respiratory distress, patent ductus arteriosus with diastolic "steal", therapeutic hypothermia, or rapid volume shifts) impair mesenteric blood flow.

Modified Bell Staging Criteria for NEC

The modified Bell staging system classifies NEC severity, guiding diagnostic imaging and clinical management.

Stage Classification Systemic Signs Gastrointestinal Signs Radiographic Findings

Stage IA Suspected NEC Temperature instability, apnea, bradycardia, lethargy Gastric residuals, mild abdominal distension, occult blood in stool Normal radiograph or mild non-specific ileus

Stage IB Suspected NEC Same as IA Same as IA plus gross bright red blood in stool Same as IA

Stage IIA Definite NEC (Mildly ill) Mild systemic depression Persistent distension, absent bowel sounds, prominent abdominal tenderness Ileus with localized bowel dilation and Pneumatosis Intestinalis

Stage IIB Definite NEC (Moderately ill) Moderate systemic toxicity, mild metabolic acidosis, thrombocytopenia Marked tenderness, abdominal wall edema/induration Extensive pneumatosis intestinalis plus Portal Venous Gas

Stage IIIA Advanced NEC (Severe, intact bowel) Severe metabolic acidosis, septic shock, hypotension, coagulopathy, neutropenia Generalized peritonitis, marked distension, abdominal wall erythema Persistent fixed dilated bowel loop, marked ascites; no free air

Stage IIIB Advanced NEC (Perforated bowel) Deteriorating shock, multiorgan failure, DIC Same as IIIA with tense, discolored peritonitic abdomen Pneumoperitoneum (free subdiaphragmatic air, "football sign", Rigler sign)

Hallmark Radiographic Features

Pneumatosis Intestinalis : Pathognomonic for definite NEC (Bell Stage II) . Appears as linear or bubbly radiolucent streaks tracking within the subserosal or submucosal layers of the bowel wall (produced by gas-producing bacteria fermenting luminal carbohydrates).

Portal Venous Gas : Branching, dendritic linear radiolucencies extending from the liver hilum toward the periphery of the hepatic silhouette. Occurs when intramural gas enters mesenteric venules and travels into the portal system.

Pneumoperitoneum : Pathognomonic for intestinal perforation (Bell Stage IIIB) . Signs include:

Subdiaphragmatic free air visible beneath the diaphragm on an upright or cross-table lateral view

Rigler Sign (Double Wall Sign) : Free peritoneal air outlines both the luminal and peritoneal surfaces of the bowel wall

Football Sign : Large volume of free air outlining the entire peritoneal cavity with the falciform ligament appearing as a vertical seam

  • Medical vs. Surgical Management of NEC Management of Necrotizing Enterocolitis
  • │
  • ┌─────────────────────────────┴─────────────────────────────┐
  • ▼ ▼
  • Medical Management (Stages I, II, IIIA) Surgical Management
  • Bowel Rest (initially NPO; duration depends on stage) Absolute Indication: PNEUMOPERITONEUM
  • Nasogastric Decompression (Low continuous suction) Relative Indications: Clinical deterioration,
  • Total Parenteral Nutrition (TPN) fixed bowel loop >24-48h, abdominal wall mass
  • Broad-Spectrum IV Antibiotics (Amp + Gent + Metronidazole) │
  • Serial Abdominal X-Rays (q6-12h: AP & Cross-table lateral) ▼
  • Supportive: Transfusions (Platelets/FFP), Inotropes ┌────────┴────────┐
  • ▼ ▼
  • Primary Peritoneal Exploratory
  • Drainage (PPD) Laparotomy with
  • (ELBW <1000g, unstable) Enterostomy
  • Medical Therapy

Complete Bowel Rest (NPO) : Stop feeds immediately and individualise duration. In improving suspected Stage I disease, reassess after 48–72 hours and consider restarting feeds if NEC is not confirmed. Confirmed medical NEC commonly needs longer bowel rest. After surgery, ERNICA 2025 suggests restarting feeds within 7 days when there are no active signs of disease or obstruction.

Gastrointestinal Decompression : Continuous low suction via a large-bore orogastric or nasogastric tube (Replogle tube) to prevent bowel distension and reduce mucosal wall tension.

Total Parenteral Nutrition (TPN) : Essential to supply fluids, electrolytes, and amino acids during prolonged starvation.

Broad-Spectrum Intravenous Antibiotics : Empiric regimens must cover Gram-positive cocci, Gram-negative enteric bacilli, and anaerobes (e.g., Ampicillin + Gentamicin (or Cefotaxime) + Metronidazole , or single-agent Meropenem , or Piperacillin-Tazobactam ).

Intensive Monitoring : Serial abdominal radiographs (supine anteroposterior and left lateral decubitus or cross-table lateral views) performed every 6 to 12 hours during acute progression to detect free air promptly.

Surgical Indications and Procedures

Absolute Surgical Indication : Pneumoperitoneum (intestinal perforation) .

Relative Surgical Indications : Refractory clinical deterioration despite maximal medical therapy, persistent fixed loop on serial radiographs over 24-48 hours, portal venous gas with worsening multiorgan failure, or positive paracentesis yielding brown fluid or bacteria on Gram stain.

Surgical Approaches :

Primary Peritoneal Drainage (PPD) : Bedside placement of a Penrose drain in the right lower quadrant under local anesthesia; primarily used for extremely low birth weight infants (<1000 g) too unstable to survive transport to the operating theatre.

Exploratory Laparotomy : Resection of non-viable, necrotic bowel segments with preservation of maximal bowel length (to prevent short bowel syndrome ), creation of an enterostomy (e.g., ileostomy) and distal mucous fistula. Primary re-anastomosis is reserved for selected stable patients with focal disease.

Neonatal Hypoglycemia: Definitions, Physiology, and Management

Neonatal hypoglycemia is the most common metabolic disturbance in the newborn period. Uncorrected hypoglycemia starves developing neuronal tissue of obligate glucose substrate, resulting in permanent neurodevelopmental injury, microcephaly, and occipital cerebral atrophy.

Normal Transitional Physiology

At birth, the sudden interruption of maternal transplacental glucose transfer triggers a sharp decline in neonatal blood glucose, reaching a physiological nadir at 1 to 2 hours of life (typically 1.8 to 2.2 mmol/L [30 to 40 mg/dL]) . In healthy term infants, counter-regulatory surges in glucagon, epinephrine, cortisol, and growth hormone stimulate hepatic glycogenolysis and gluconeogenesis, while insulin secretion is suppressed. Blood glucose concentrations stabilize at >2.6 mmol/L (>47 mg/dL) by 12 to 24 hours of life.

Clinical Thresholds and At-Risk Populations

Operational Threshold : Thresholds differ between national protocols. The CPS pathway used below treats <2.6 mmol/L (47 mg/dL) in at-risk infants during the first 72 hours ; symptoms require immediate assessment and treatment.

Treatment Targets : Aim for ≥2.6 mmol/L during this transitional period and ≥3.3 mmol/L after 72 hours for persistent hypoglycaemia. Confirmed hyperinsulinism requires a specialist target in the normal range, generally 3.9–5.6 mmol/L .

High-Risk Cohorts Requiring Screening :

Hyperinsulinism : Infants of Diabetic Mothers (IDM) (maternal hyperglycemia drives fetal pancreatic islet beta-cell hyperplasia; abrupt cessation of maternal glucose at delivery leaves severe hyperinsulinemia), Large for Gestational Age (LGA, birth weight >90th percentile), Beckwith-Wiedemann syndrome.

Substrate / Glycogen Depletion : Small for Gestational Age (SGA, birth weight <10th percentile) , intrauterine growth restriction (IUGR), preterm infants (<37 weeks).

Increased Glucose Consumption : Perinatal asphyxia, sepsis, hypothermia, respiratory distress syndrome, polycythemia.

Clinical Presentation

Symptoms are non-specific and frequently absent (mandating routine point-of-care screening in all at-risk neonates):

  • Jitteriness, tremors, exaggerated Moro reflex, irritability
  • Lethargy, hypotonia, weak suck, poor feeding
  • Hypothermia, temperature instability
  • Tachypnea, cyanosis, recurrent apnea
  • Focal or generalized seizures, stupor, coma
  • Acute Management Algorithm Neonatal Hypoglycaemia: CPS First-72-Hour Pathway
  • |
  • +--------------------------+----------------------------+
  • | |
  • Asymptomatic, 1.8–2.5 mmol/L Symptoms with low glucose,
  • or very low glucose <1.8 mmol/L
  • Feed + consider 40% buccal glucose gel |
  • (0.5 mL/kg = 200 mg/kg) Urgent IV D10W, commonly 2 mL/kg,
  • Recheck after 30 minutes followed by infusion (GIR 4–8 mg/kg/min)
  • If unresponsive: IV glucose |
  • Recheck promptly; titrate to target
  • ≥2.6 mmol/L during transition
  • Persistent after 72h: ≥3.3 mmol/L
  • |
  • Recurrent episodes or unusually high GIR
  • (e.g. >8 mg/kg/min) → investigate cause
  • Obtain critical sample without delaying rescue
  • Seek neonatal/endocrine specialist guidance
  • Glucose Infusion Rate (GIR) Calculation

GIR (mg/kg/min) = Fluid Rate (mL/kg/day) × % Dextrose Concentration 144 \text{GIR (mg/kg/min)} = \frac{\text{Fluid Rate (mL/kg/day)} \times \% \text{ Dextrose Concentration}}{144} GIR (mg/kg/min) = 144 Fluid Rate (mL/kg/day) × % Dextrose Concentration ​ Alternatively: GIR = IV Rate (mL/hour) × % Dextrose 6 × Weight (kg) \text{Alternatively: } \text{GIR} = \frac{\text{IV Rate (mL/hour)} \times \% \text{ Dextrose}}{6 \times \text{Weight (kg)}} Alternatively: GIR = 6 × Weight (kg) IV Rate (mL/hour) × % Dextrose ​

Example Calculation : A 3.0 kg infant receiving 10% Dextrose at 100 mL/kg/day: GIR = 100 × 10 144 = 6.94 mg/kg/min ( normal starting target: 4 to 8 mg/kg/min ) \text{GIR} = \frac{100 \times 10}{144} = 6.94\text{ mg/kg/min} \quad (\text{normal starting target: 4 to 8 mg/kg/min}) GIR = 144 100 × 10 ​ = 6.94 mg/kg/min ( normal starting target: 4 to 8 mg/kg/min )

Warning

Avoid Concentrated Dextrose Boluses : When administering a dextrose bolus for acute neonatal hypoglycemia, always use 10% Dextrose (D10W) at 2 mL/kg . Never administer 25% or 50% dextrose boluses; high-concentration boluses cause severe hyperosmolality, chemical phlebitis, and provoke immediate, massive rebound hyperinsulinemia, plunging the infant into recurrent refractory hypoglycemia.

The "Critical Blood Sample"

Recurrent/persistent hypoglycaemia or unusually high glucose requirements (e.g. GIR >8 mg/kg/min ) warrant investigation for hyperinsulinism, endocrine deficiency or metabolic disease. Hyperinsulinism may be acquired/perinatal-stress related or genetic. During a low glucose episode, preferably plasma glucose <2.8 mmol/L , collect a critical sample before correction when feasible, but never delay glucose rescue :

  • Hormones : Insulin, C-peptide, Cortisol, Growth Hormone
  • Intermediary Metabolites : Free Fatty Acids, Beta-hydroxybutyrate (ketones)
  • Metabolic Profile : Lactate, Ammonia, Acylcarnitine profile, Blood gas
  • Urine : Ketones and organic acids

Hyperinsulinism Profile : Suppressed beta-hydroxybutyrate and free fatty acids , high glucose requirement and a large glucose response to glucagon demonstrate inappropriate insulin action. Insulin may be low or undetectable, so its concentration alone cannot exclude the diagnosis. Diazoxide (5–15 mg/kg/day oral, a beta-cell K-ATP-channel opener) is specialist-directed first-line therapy when appropriate; monitor for fluid retention and pulmonary hypertension.

Newborn Bloodspot Screening (NBS / Guthrie Test)

Newborn bloodspot screening (the Guthrie test) identifies severe, treatable congenital disorders before clinical symptom onset, preventing permanent intellectual disability, metabolic decompensation, or death.

Technical Execution and Methodology

Timing : Collect heel-prick blood onto a standard filter-paper card at the national programme’s scheduled age: for example, 36–72 hours in Germany and day 5 in the UK (birth is day 0).

Feeding and Repeat Samples : Do not delay routine sampling until milk feeds are established . Record feeding, parenteral nutrition and transfusion details, and follow the screening laboratory’s repeat-sample policy.

Primary Analytical Method : Tandem Mass Spectrometry (MS/MS) , which analyzes dozens of amino acids, acylcarnitines, and organic acid intermediates from a single 3 mm dried bloodspot punch.

Five Common Screened Conditions: Check the National Panel

Condition Primary Marker Pathophysiology & Clinical Impact if Untreated Definitive Confirmation & Urgent Management

Phenylketonuria (PKU) Elevated Phenylalanine and elevated Phe/Tyr ratio Autosomal recessive deficiency of Phenylalanine Hydroxylase (PAH) ; toxic Phe accumulation causes irreversible brain damage, microcephaly, seizures, "mousy" odor, fair hair/blue eyes Confirmation via plasma amino acids; Low-phenylalanine diet initiated before 10-14 days of life ; target Phe 120-360 µmol/L; trial of sapropterin (BH4)

Congenital Hypothyroidism (CH) Elevated TSH (primary thyroid failure) Most common preventable cause of intellectual disability (1:2000-3000); Thyroid dysgenesis (85%); presents with prolonged jaundice, large fontanelles, umbilical hernia, macroglossia, cretinism Serum free T4 and TSH confirmation; Oral Levothyroxine (10-15 µg/kg/day) started before 14 days of life (optimally <7-10 days)

Cystic Fibrosis (CF) Elevated Immunoreactive Trypsinogen (IRT) Autosomal recessive CFTR mutations (F508del); blocked pancreatic ducts cause IRT spillover; progressive bronchiectasis, exocrine pancreatic insufficiency, meconium ileus Second-tier CFTR DNA mutation panel, followed by Sweat Chloride Test (pilocarpine iontophoresis, diagnostic if ≥60 mmol/L ); PERT + vitamins A, D, E, K

Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) Elevated Octanoylcarnitine (C8) Autosomal recessive defect in mitochondrial beta-oxidation of fatty acids (ACADM gene, c.985A>G); inability to generate ketones during fasting causes hypoketotic hypoglycemia , Reye-like coma, sudden death Urine organic acids (dicarboxylic aciduria) + ACADM sequencing; Strict avoidance of fasting (max 4h in neonates), emergency high-carbohydrate regimen during illness; MCT oil contraindicated

Sickle Cell Disorders (SCD) Abnormal Hb pattern: FS (HbF + HbS, absent HbA) Homozygous mutation in beta-globin gene (HbSS); functional asplenia develops early in infancy, predisposing to catastrophic Streptococcus pneumoniae sepsis and splenic sequestration Hemoglobin electrophoresis / HPLC / IEF; Prophylactic oral Penicillin V starting at 2 to 3 months of life ; pneumococcal conjugate/polysaccharide vaccination

Tip

MCADD Exam Pearl : The hallmark of MCADD is hypoketotic hypoglycemia triggered by fasting or intercurrent viral illness (such as gastroenteritis). In contrast to hyperinsulinism (which also causes hypoketotic hypoglycemia), MCADD exhibits elevated free fatty acids that cannot be metabolized into ketone bodies, with characteristic elevated octanoylcarnitine (C8) and dicarboxylic aciduria.